RESEARCH HIGHLIGHTS Nature Reviews Clinical Oncology advance online publication 3 June 2014; doi:10.1038/nrclinonc.2014.92


NEPA—a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting C


ausea and vomiting are two of the most common adverse effects of many cancer treatments and are especially associated with chemotherapy. The risk of chemotherapy-induced nausea and vomiting (CINV) varies based on the type of treatment received and on several external factors. Some chemotherapy regimens, such as cisplatin, are highly emetogenic (HEC) with an high incidence of CINV (>90%), whereas others are moderately emetogenic (MEC) with a 30–90% incidence of nausea and vomiting. CINV has a multifactorial origin, involving several neurotransmitters and receptors. Antiemetic guidelines recommend the use of combination regimens—over several days—to prevent and control CINV; however, adherence to such guidelines is suboptimal and many patients remain undertreated. Three studies published in the Annals of Oncology have now demonstrated that a single oral dose of the NEPA combination regimen is effective and safe in preventing CINV, providing an improved method to control such adverse effect and to possibly obtain higher adherence to the guidelines and to the chemotherapy regimens. The NEPA regimen is a novel oral fixed-dose combination of netupitant (a highly selective neurokinin-1 receptor antagonist), and palonosetron (PALO, a 5-hydroxytryptamine type 3 receptor antagonist) that can deliver guideline treatments in a convenient single dose. In the first study, Paul Hesketh and colleagues performed a multicentre, randomized, double blind phase II study that accrued 694 patients, to establish the optimal fixed-dose of NEPA, and tested three different concentrations of netupitant (100, 200 or 300 mg) in combination with 0.50 mg of oral PALO and dexamethasone (DEX). As Hesketh emphasizes, “the objective was to demonstrate superior CINV prevention with the NEPA dose combinations over oral PALO (and DEX),” in a HEC cisplatin

setting. All three doses tested showed superior complete response during the overall phase (0–120 h post-treatment) and delayed phase (25–120 h posttreatment). However, only the NEPA300 dose showed superiority compared with PALO in the acute phase (within 24 h of chemotherapy) and for all the secondary efficacy end points (no emesis, no significant nausea and complete protection). Hesketh highlights that “on the basis of these results, the NEPA300 oral fixed-dose combination was selected for continued development.” In the second study, Matti Aapro and colleagues randomized 1,455 chemotherapy-naive patients to receive the optimal NEPA300 oral dose or a single oral dose of PALO in an anthracycline-based (AC) MEC setting. In this phase III trial, NEPA300 was superior to PALO during all phases postchemotherapy for the primary efficacy end point of complete response and also during the delayed and overall phases for the secondary end points of no emesis, no significant nausea and complete protection. Aapro says that “these efficacy benefits translated into a clinical benefit, as a greater proportion of NEPA-treated patients reported no impact on daily routine due to their nausea or vomiting.” He continues, “the consistent superiority of NEPA over PALO across all end points during the delayed phase is a particularly important finding, as the delayed phase has remained a challenge in most clinical settings.” Finally, in the third study, Richard Gralla and colleagues randomly assigned 413 patients receiving multiple cycles of HEC or MEC to receive NEPA300 or PALO (plus aprepitant). In this phase III trial, the researchers demonstrated that NEPA300 is highly effective in preventing CINV and that this combination retains its efficacy over multiple cycles of chemotherapy. Notably, 75% of patients completed at least four cycles of chemotherapy and 40%


H N E E M P R O E V E I A N T I O N H D E completed six cycles. U In addition to its R improved efficacy, C N A safety of NEPA U S E A was also evaluated P in these three trials, D NPG concluding that Y NEPA is safe and well tolerated. Gralla emphasizes “our study is one of the most extensive antiemetic studies showing such a degree of cardiac safety” and continues, “the NEPA combination is a very simple all oral single-dose regimen to aid adherence to antiemetic prevention, and achieves this in some of the most difficult and frequent emetic settings.” All the authors agree that further trials will have to assess the efficacy of NEPA in minimizing the more challenging nausea symptom, in higher-risk patients and in other treatments such as radiotherapy. Alessia Errico Original articles Gralla, R. J. et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol. doi:10.1093/ annonc/mdu096 | Hesketh, P. J. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann. Oncol. doi:10.1093/annonc/mdu110 | Aapro, M. A. et al. Randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. doi:10.1093/annonc/mdu101

ADVANCE ONLINE PUBLICATION © 2014 Macmillan Publishers Limited. All rights reserved

Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting.

Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting. - PDF Download Free
694KB Sizes 2 Downloads 4 Views

Recommend Documents

Prevention and management of chemotherapy-induced nausea and vomiting.
Nausea and vomiting are among the most frequently experienced toxic side-effects associated with chemotherapy. Although nausea and vomiting can result from surgery or radiotherapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the mo

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Chemotherapy-induced nausea and vomiting: optimizing prevention and management.
Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. Despite advances in the prevention and management o

Chemotherapy-Induced Nausea and Vomiting.
Despite treatment advances, nausea and vomiting, especially anticipatory nausea and vomiting, delayed nausea and vomiting and nausea alone, are still the most common, expected and feared side effects among patients receiving chemotherapy. Of the 70 t

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
Olanzapine is an atypical antipsychotic agent of the thiobenzodiazepine class. It blocks multiple neurotransmitter receptors including dopaminergic at D1, D2, D3, D4 brain receptors, serotonergic at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholami

Treatment of Nausea and Vomiting During Chemotherapy.
Nausea and vomiting are two of the most troubling side effects patients experience during chemotherapy. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still a

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
To establish the role of antiemetic therapy with neurokinin-1 (NK1) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.)

Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting?
Postoperative nausea and vomiting (PONV) remains a problem in the postoperative period. Previous PONV in oncology patients has recently been associated with chemotherapy-induced nausea and vomiting (CINV). We assessed if CINV could improve Apfel's he

Anticipatory nausea and vomiting due to chemotherapy.
As a specific variation of chemotherapy-induced nausea and vomiting, anticipatory nausea and vomiting (ANV) appears particularly linked to psychological processes. The three predominant factors related to ANV are classical conditioning; demographic a